Skip to main content

Advertisement

SpringerLink
Log in

Beta-Blockers, Calcium Channel Blockers, and Mortality in Stable Coronary Artery Disease

  • Ischemic Heart Disease (D Mukherjee, Section Editor)
  • Published:
Current Cardiology Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

To examine the current clinical evidence behind the use of calcium channel blockers (CCB) and beta-blockers (BB) for the treatment of patients with stable coronary artery disease (SCAD) and their effect on mortality.

Recent Findings

Current evidence suggests that BB use as a first line antianginal medication is associated with lower 5-year all-cause mortality only in patients who had MI within a year. This could be driven due to their effects reducing the sympathetic neuro-hormonal activation of more acutely ill patients. The use of CCB as an antianginal therapy, although proven effective in multiple trials both as monotherapy and combined with other agents, has not shown mortality benefit.

Summary

Both BB and CCB are effective antianginals, and the selection among them depends on the patient clinical presentation and comorbidities. BB are the only ones that have shown survival benefit in SCAD, particularly the first year post-MI.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. . Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, et al. 2013 ESC guidelines on the management of stable coronary artery disease: the task force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013;34: 2949–3003. doi: https://doi.org/10.1016/j.jacc.2014.09.017

    Article  Google Scholar 

  2. Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, et al. 2012 ACCF/AHA/ACP/AATS/ PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular (probably a typo)Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2012;126:e354–471. https://doi.org/10.1016/j.jacc.2012.07.013.

    Article  PubMed  Google Scholar 

  3. Steg PG, Bhatt DL, Wilson PW, D’Agostino R Sr, Ohman EM, Rother J, et al. One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA. 2007;297(11):1197–206. https://doi.org/10.1001/jama.297.11.1197.

    Article  CAS  PubMed  Google Scholar 

  4. Bangalore S, Bhatt DL, Steg PG, Weber MA, Boden WE, Hamm CW, et al. Beta-blockers and cardiovascular events in patients with and without myocardial infarction: post-hoc analysis from the CHARISMA trial. Circ Cardiovasc Qual Outcomes. 2014;7:872–81. https://doi.org/10.1161/CIRCOUTCOMES.114.001073.

    Article  PubMed  Google Scholar 

  5. Daly CA, De Stavola B, Sendon JL, Tavazzi L, Boersma E, Clemens F, et al. Predicting prognosis in stable angina: results from the Euro heart survey of stable angina: prospective observational study. BMJ. 2006;332:262–7. https://doi.org/10.1136/bmj.38695.605440.AE.

    Article  PubMed  PubMed Central  Google Scholar 

  6. National Institutes of Health NH, Lung, and Blood Institute. Morbidity & Mortality: 2012 Chart Book on Cardiovascular, Lung, and Blood Diseases. Bethesda: National Heart, Lung, and Blood Institute; 2012.

    Google Scholar 

  7. • Puymirat E, Riant E, Aissaoui N, et al. Beta blockers and mortality after myocardial infarction in patients without heart failure: multicentre prospective cohort study. BMJ. 2016;354:i4801. https://doi.org/10.1136/bmj.i4801 After MI, early BB use was associated with reduced 30-day mortality and discontinuation one year was not associated with higher 5-year mortality.

    Article  PubMed  PubMed Central  Google Scholar 

  8. • Neumann A, Maura G, Weill A, Alla F, Danchin N. Clinical events after discontinuation of β-blockers in patients without heart failure optimally treated after acute myocardial infarction: a cohort study on the French Healthcare Databases. Circ Cardiovasc Qual Outcomes. 2018;11(4):e004356. https://doi.org/10.1161/CIRCOUTCOMES.117.004356 Discontinuation of BB one year after MI showed increased risk of death due to ACS, although not significant for all-cause mortality.

    Article  PubMed  Google Scholar 

  9. Bangalore S, Steg G, Deedwania P, Crowley K, Eagle KA, Goto S, et al. Beta-blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308:1340–9. https://doi.org/10.1001/jama.2012.12559.

    Article  CAS  PubMed  Google Scholar 

  10. Poole-Wilson PA, Lubsen J, Kirwan BA, van Dalen FJ, Wagener G, Danchin N, et al. Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomized controlled trial. Lancet. 2004;364:849–57. https://doi.org/10.1016/S0140-6736(04)16980-8.

    Article  CAS  PubMed  Google Scholar 

  11. Dargie HJ, Ford I, Fox KM, TIBET Study Group. Total Ischaemic Burden European Trial (TIBET) Effects of ischaemia and treatment with atenolol, nifedipine SR and their combination on outcome in patients with chronic stable angina. Eur Heart J. 1996;17(1):104–12. https://doi.org/10.1093/oxfordjournals.eurheartj.a014668.

    Article  CAS  PubMed  Google Scholar 

  12. Wallace WA, Wellington KL, Chess MA, Liang CS. Comparison of nifedipine gastrointestinal therapeutic system and atenolol on antianginal efficacies and exercise hemodynamic responses in stable angina pectoris. Am J Cardiol. 1994;73:23–8. https://doi.org/10.1016/0002-9149(94)90721-8.

    Article  CAS  PubMed  Google Scholar 

  13. van de Ven LL, Vermeulen A, Tans JG, Tans AC, Liem KL, Lageweg NC, et al. Which drug to choose for stable angina pectoris: a comparative study between bisoprolol and nitrates. Int J Cardiol. 1995;47:217–23. https://doi.org/10.1016/0167-5273(94)02194-N.

    Article  PubMed  Google Scholar 

  14. Steffensen R, Grande P, Pedersen F, Haunso S. Effects of atenolol and diltiazem on exercise tolerance and ambulatory ischaemia. Int J Cardiol. 1993;40:143–53. https://doi.org/10.1016/0167-5273(93)90277-N.

    Article  CAS  PubMed  Google Scholar 

  15. Fox KM, Mulcahy D, Findlay I, Ford I, Dargie HJ, The Total Ischaemic Burden European Trial (TIBET). Effects of atenolol, nifedipine SR and their combination on the exercise test and the total ischaemic burden in 608 patients with stable angina. The TIBET Study Group. Eur Heart J. 1996;17:96–103. https://doi.org/10.1093/oxfordjournals.eurheartj.a014699.

    Article  CAS  PubMed  Google Scholar 

  16. de Vries RJ, van den Heuvel AF, Lok DJ, Claessens RJ, Bernink PJ, Pasteuning WH, et al. Nifedipine gastrointestinal therapeutic system versus atenolol in stable angina pectoris. The NetherlandsWorking Group on Cardiovascular Research (WCN). Int J Cardiol. 1996;57:143–50. https://doi.org/10.1016/S0167-5273(96)02806-9.

    Article  PubMed  Google Scholar 

  17. Kawanishi DT, Reid CL, Morrison EC, Rahimtoola SH. Response of angina and ischemia to long-term treatment in patients with chronic stable angina: a doubleblind randomized individualized dosing trial of nifedipine, propranolol and their combination. J Am Coll Cardiol. 1992;19:409–17. https://doi.org/10.1016/0735-1097(92)90499-D.

    Article  CAS  PubMed  Google Scholar 

  18. Meyer TE, Adnams C, Commerford P. Comparison of the efficacy of atenolol and its combination with slow-release nifedipine in chronic stable angina. Cardiovasc Drugs Ther. 1993;7:909–13. https://doi.org/10.1007/BF00877726.

    Article  CAS  PubMed  Google Scholar 

  19. Rehnqvist N, Hjemdahl P, Billing E, Bjorkander I, Eriksson SV, Forslund L, et al. Effects of metoprolol vs verapamil in patients with stable angina pectoris. The Angina Prognosis Study in Stockholm (APSIS). Eur Heart J. 1996;17:76–81. https://doi.org/10.1093/oxfordjournals.eurheartj.a014695.

    Article  CAS  PubMed  Google Scholar 

  20. Packer M, Bristow MR, Cohn JN, Colucci WS, Fowler MB, Gilbert EM, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. U.S. Carvedilol Heart Failure Study Group. N Engl J Med. 1996;334:1349–55. https://doi.org/10.1056/NEJM199605233342101.

    Article  CAS  PubMed  Google Scholar 

  21. CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9–13. https://doi.org/10.1016/S0140-6736(98)11181-9.

    Article  Google Scholar 

  22. Yusuf S, Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease. I Treatments following myocardial infarction. JAMA. 1988;260:2088–93. https://doi.org/10.1001/jama.1988.03410140100032.

    Article  CAS  PubMed  Google Scholar 

  23. Goldberger JJ, Bonow RO, Cuffe M, Liu L, Rosenberg Y, Shah PK, et al. Effect of beta-blocker dose on survival after acute myocardial infarction. J Am Coll Cardiol. 2015;66:1431–41. https://doi.org/10.1016/j.jacc.2015.07.047.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  24. Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, et al. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. JAMA. 2000;283:1295–302. https://doi.org/10.1001/jama.283.10.1295.

    Article  CAS  PubMed  Google Scholar 

  25. Andersson C, Shilane D, Go AS, Chang TI, Kazi D, Solomon MD, et al. Beta-blocker therapy and cardiac events among patients with newly diagnosed coronary heart disease. J Am Coll Cardiol. 2014;64:247–52. https://doi.org/10.1016/j.jacc.2014.04.042.

    Article  CAS  PubMed  Google Scholar 

  26. • Sorbets E, Steg PG, Young R, Danchin N, Greenlaw N, Ford I, et al. β-blockers, calcium antagonists, and mortality in stable coronary artery disease: an international cohort study. Eur Heart J. 2019;40(18):1399–407. https://doi.org/10.1093/eurheartj/ehy811 Large contemporary cohort of SCAD showing the outcomes associated with CCB and BB.

    Article  PubMed  PubMed Central  Google Scholar 

  27. Wilson PW, D’Agostino R Sr, Bhatt DL, Eagle K, Pencina MJ, Smith SC, et al. REACH Registry. An international model to predict recurrent cardiovascular disease. Am J Med. 2012;125:695–703.e1. https://doi.org/10.1016/j.amjmed.2012.01.014.

    Article  PubMed  Google Scholar 

  28. • Malik AH, Shetty S, Kar K, El Accaoui R. Effect of β-blocker therapy in diabetic patients with stable coronary heart disease: a meta-analysis. J Geriat Cardiol. 2019;16(3):291–7. https://doi.org/10.11909/j.issn.1671-5411.2019.03.008 BB therapy in diabetic patients with SCHD appears to be linked to higher mortality.

    Article  CAS  Google Scholar 

  29. Motivala AA, Parikh V, Roe M, Dai D, Abbott JD, Prasad A, et al. Predictors, trends, and outcomes (among older patients≥ 65 years of age) associated with beta-blocker use in patients with stable angina undergoing elective percutaneous coronary intervention: insights from the NCDR registry. J Am Coll Cardiol Intv. 2016;9(16):1639–48. https://doi.org/10.1016/j.jcin.2016.05.048.

    Article  Google Scholar 

  30. Visser CA, Koolen JJ, van Wezel H, Dunning AJ. Hemodynamics of nicardipine in coronary artery disease. Am J Cardiol. 1987;59(17):J9–12. https://doi.org/10.1016/0002-9149(87)90207-4.

    Article  Google Scholar 

  31. Opie LH. Calcium channel antagonists in the treatment of coronary artery disease: fundamental pharmacological properties relevant to clinical use. Prog Cardiovasc Dis. 1996;38(4):273–90. https://doi.org/10.1016/S0033-0620(96)80014-4.

    Article  CAS  PubMed  Google Scholar 

  32. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, et al. A calcium antagonist vs a noncalcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003;290:2805–16. https://doi.org/10.1001/jama.290.21.2805.

    Article  CAS  PubMed  Google Scholar 

  33. Ried LD, Tueth MJ, Handberg E, Kupfer S, Pepine CJ. A study of antihypertensive drugs and depressive symptoms (SADD-Sx) in patients treated with a calcium antagonis versus an atenolol hypertension treatment strategy in the International Verapamil SR-Trandolapril Study (INVEST). Psychosom Med. 2005;67:398–406. https://doi.org/10.1097/01.psy.0000160468.69451.7f.

    Article  CAS  PubMed  Google Scholar 

  34. Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA. 2004;292:2217–25. https://doi.org/10.1001/jama.292.18.2217.

    Article  CAS  PubMed  Google Scholar 

  35. Frishman WH, Glasser S, Stone P, Deedwania PC, Johnson M, Fakouhi TD. Comparison of controlled-onset, extended-release verapamil with amlodipine and amlodipine plus atenolol on exercise performance and ambulatory ischemia in patients with chronic stable angina pectoris. Am J Cardiol. 1999;83:507–14. https://doi.org/10.1016/S0002-9149(98)00904-7.

    Article  CAS  PubMed  Google Scholar 

  36. Bangalore S, Parkar S, Messerli FH. Long-acting calcium antagonists in patients with coronary artery disease: a meta-analysis. Am J Med. 2009;122(4):356–65. https://doi.org/10.1016/j.amjmed.2008.09.043.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cardiovascular Diseases, Department of Internal Medicine, Texas Tech University Health Sciences Center, 4800 Alberta Avenue, El Paso, TX, 79905, USA

    Jose B. Cruz Rodriguez & Haider Alkhateeb

Authors
  1. Jose B. Cruz Rodriguez
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Haider Alkhateeb
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jose B. Cruz Rodriguez.

Ethics declarations

Conflict of Interest

Jose B. Cruz Rodriguez and Haider Alkhateeb declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article is part of the Topical Collection on Ischemic Heart Disease

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cruz Rodriguez, J.B., Alkhateeb, H. Beta-Blockers, Calcium Channel Blockers, and Mortality in Stable Coronary Artery Disease. Curr Cardiol Rep 22, 12 (2020). https://doi.org/10.1007/s11886-020-1262-1

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11886-020-1262-1

Keywords

Search

Navigation